Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice

Life Sciences

Volumn 87, Issue 13-14, 2010, Pages 405-410

  Yang, Keum Jin ^a   Noh, Jung Ran ^a   Kim, Yong Hoon ^a   Gang, Gil Tae ^a   Hwang, Jung Hwan ^a   Yang, Suk Jin ^a   Yeom, Young Il ^a   Lee, Chul Ho ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Db db mouse; Gene expression; Lipid metabolism; Thiazolidinediones; White adipose tissue

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE 1B; CARNITINE PALMITOYLTRANSFERASE I; CD36 ANTIGEN; CHOLESTEROL; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID TRANSPORTER; GLUCOSE; ISOMERASE; LIPID; MESSENGER RNA; PERILIPIN; PERILIPIN A; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; TRIOSEPHOSPHATE ISOMERASE 1; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIACYLGLYCEROL ACYLTRANSFERASE; GLUCOSE BLOOD LEVEL;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENERGY EXPENDITURE; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LIPID TRANSPORT; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OBESITY; SURFACE PROPERTY; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; METABOLISM;

ACYL-COA DEHYDROGENASE; ADIPOSE TISSUE, WHITE; ANIMALS; ANTIGENS, CD36; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIACYLGLYCEROL O-ACYLTRANSFERASE; FATTY ACID TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES; TRIGLYCERIDES;

ANIMALIA; MUS;

EID: 77956932456     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.08.002     Document Type: Article

References (30)

1. Benton C.R., Koonen D.P., Calles-Escandon J., Tandon N.N., Glatz J.F., Luiken J.J., Heikkila J.J., Bonen A. Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. The Journal of Physiology 2006, 573(Pt 1):199-210.
2. Beysen C., Murphy E.J., Nagaraja H., Decaris M., Riiff T., Fong A., Hellerstein M.K., Boyle P.J. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. Journal of Lipid Research 2008, 49(12):2657-2663.
3. Chatelain F., Kohl C., Esser V., McGarry J.D., Girard J., Pegorier J.P. Cyclic AMP and fatty acids increase carnitine palmitoyltransferase I gene transcription in cultured fetal rat hepatocytes. European Journal of Biochemistry 1996, 235(3):789-798.
4. Chawla A., Schwarz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135(2):798-800.
5. Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 2009, 51(4):771-784.
6. Derosa G., Salvadeo S.A. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Current Clinical Pharmacology 2008, 3(2):77-84.
7. Derosa G., Cicero A.F., Gaddi A., Ragonesi P.D., Fogari E., Bertone G., Ciccarelli L., Piccinni M.N. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical Therapeutics 2004, 26(5):744-754.
8. Derosa G., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., Pricolo F., Salvadeo S.A., Montagna L., Gravina A., Ferrari I., Paniga S., Cicero A.F. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy & Therapeutics 2006, 31(4):375-383.
9. Eleftheriadou I., Grigoropoulou P., Katsilambros N., Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Current Diabetes Reviews 2008, 4(4):340-356.
10. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., Jacober S.J. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28(7):1547-1554.
11. Guo L., Zhang L., Sun Y., Muskhelishvili L., Blann E., Dial S., Shi L., Schroth G., Dragan Y.P. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Molecular Diversity 2006, 10(3):349-360.
12. Kanda T., Brown J.D., Orasanu G., Vogel S., Gonzalez F.J., Sartoretto J., Michel T., Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. The Journal of Clinical Investigation 2009, 119(1):110-124.
13. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65(3):385-411.
14. Lee M.Y., Koh J.H., Nam S.M., Jung P.M., Sung J.K., Kim S.Y., Shin J.Y., Shin Y.G., Chung C.H. Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes. Yonsei Medical Journal 2008, 49(6):901-908.
15. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123(6):993-999.
16. Liu L.F., Purushotham A., Wendel A.A., Koba K., DeIuliis J., Lee K., Belury M.A. Regulation of adipose triglyceride lipase by rosiglitazone. Diabetes, Obesity & Metabolism 2009, 11(2):131-142.
17. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. The Journal of Biological Chemistry 1998, 273(27):16710-16714.
18. Powell D.R. Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo. Obesity Reviews 2006, 7(1):89-108.
19. Rong J.X., Qiu Y., Hansen M.K., Zhu L., Zhang V., Xie M., Okamoto Y., Mattie M.D., Higashiyama H., Asano S., Strum J.C., Ryan T.E. Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 2007, 56(7):1751-1760.
20. Seo Y.S., Kim J.H., Jo N.Y., Choi K.M., Baik S.H., Park J.J., Kim J.S., Byun K.S., Bak Y.T., Lee C.H., Kim A., Yeon J.E. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Journal of Gastroenterology and Hepatology 2008, 23(1):102-109.
21. Shen W.J., Patel S., Yu Z., Jue D., Kraemer F.B. Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissue. Biochimica et Biophysica Acta 2007, 1771(2):177-184.
22. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47(4):507-514.
23. Stafford J.M., Elasy T. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vascular Health and Risk Management 2007, 3(4):503-510.
24. Tan G.D., Savage D.B., Fielding B.A., Collins J., Hodson L., Humphreys S.M., O'Rahilly S., Chatterjee K., Frayn K.N., Karpe F. Fatty acid metabolism in patients with PPARgamma mutations. The Journal of Clinical Endocrinology and Metabolism 2008, 93(11):4462-4470.
25. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes & Development 1994, 8(10):1224-1234.
26. Viswanadha S., Londos C. Determination of lipolysis in isolated primary adipocytes. Methods in Molecular Biology 2008, 456:299-306.
27. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lehmann J.M. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Journal of Medicinal Chemistry 1996, 39(3):665-668.
28. Winkelmayer W.C., Setoguchi S., Levin R., Solomon D.H. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Archives of Internal Medicine 2008, 168(21):2368-2375.
29. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., Oplinger J.A., Kliewer S.A., Gampe R.T., McKee D.D., Moore J.T., Willson T.M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proceeding of the National Academy of Sciences of the United States of America 2001, 98(24):13919-13924.
30. Yamanaka M., Itakura Y., Tsuchida A., Nakagawa T., Noguchi H., Taiji M. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Diabetes, Obesity & Metabolism 2007, 9(6):879-888.